> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# SightGlass Vision Begins Pivotal Trial on Spectacle Lens
- URL: https://www.fdaweb.com/sightglass-vision-begins-pivotal-trial-on-spectacle-lens/
- Published: 2019-01-10T12:00:00.000Z
- Updated: 2026-09-15T00:53:37.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5143133

SightGlass Vision, a medical device company developing spectacle lenses to slow the progression of nearsightedness or myopia in children, has been given an FDA green light to begin a pivotal clinical trial called CYPRESS. The study will evaluate the safety and efficacy of the company’s novel lenses compared to standard spectacles to reduce the rate of progression of myopia in children aged six-to-nine years old. Glasses and contact lenses currently available in the U.S. only correct myopia, but do not help prevent it from getting worse, according to the company.

The double-blinded, randomized controlled clinical trial plans to enroll 255 patients across 14 sites in the U.S. and Canada. The primary outcome measure is myopia progression (change in axial length and change in spherical equivalent refraction) over 36 months, SightGlass says. Trial participants will be able to choose from a variety of eyeglass frames and will be asked to use one of three types of lenses instead of their normal glasses.